港股異動丨國藥科技盤初一度衝高至20% 與珠海華髮簽訂協議 且中期業績激增6倍
格隆匯2月18日丨國藥科技股份(08156.HK)延續昨日強勢走高,今日盤初大幅高開衝高至20%。現漲幅回落至9.29%,報0.3港元,暫成交808萬港元,最新總市值12.3億港元。國藥科技股份(08156.HK)與珠海華髮簽訂戰略合作框架協議,董事會相信,憑着集團在醫藥市場的業務資源,以及市場運營的豐富經驗積累及戰略股東和合作夥伴的支持,與珠海華髮攜手合作,解決抗擊疫情第一線及民用市場對醫療用品的燃眉之急。本次戰略合作能夠在互利共贏的基礎上為雙方帶來商業效益。日前公司公佈,截至2019年12月31日止6個月,實現收入約8738萬港元,同比增606.10%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.